Stock Events

Stock Events

Kubota Pharmaceutical 

¥92
10
+¥2+2.22% Today

Statistics

Day High
94
Day Low
90
52W High
350
52W Low
41
Volume
1,954,800
Avg. Volume
10,957,761
Mkt Cap
3.89B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-5.93
-3.74
-1.56
0.63
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2013
2014
2015
2016
2017
2018
0Revenue
-6.09BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4596.TSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals, Inc. competes in the development of ophthalmology treatments, similar to Kubota's focus on eye diseases.
Novartis
NVS
Mkt Cap297.35B
Novartis AG, through its ophthalmology division, competes directly in the eye care pharmaceutical market.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG develops treatments for various eye conditions, competing in the same space as Kubota.
Bausch Health Companies
BHC
Mkt Cap2.09B
Bausch Health Companies Inc., through its eye health products, is a direct competitor in the ophthalmic pharmaceutical market.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie Inc. entered the eye care market through its acquisition of Allergan, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, with its vision care segment, competes in the broader eye health market.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has a portfolio of ophthalmology treatments, positioning it as a competitor.
Takeda Pharmaceutical
TAK
Mkt Cap57.12B
Takeda Pharmaceutical Company Limited has ventured into ophthalmology, making it a competitor.
Sanofi
SNY
Mkt Cap113.88B
Sanofi develops treatments for ophthalmological conditions, competing with Kubota.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC, though not heavily focused on ophthalmology, has interests in expanding its portfolio in areas that could compete with Kubota.

About

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices in the ophthalmic field worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device, a home-based and patient self-monitoring optical coherence tomography devices to treat wet age-related macular degeneration and diabetic macular edema, which brings retinal edema and reduction in visual acuity; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Show more...
CEO
Dr. Ryo Kubota
Employees
8
Country
Japan
ISIN
JP3266500002

Listings

TSE
JP
4596.TSE

0 Comments

Share your thoughts

FAQ

What is Kubota Pharmaceutical stock price today?▼
The current price of 4596.TSE is ¥92 JPY — it has increased by +2.22% in the past 24 hours. Watch Kubota Pharmaceutical stock price performance more closely on the chart.
What is Kubota Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kubota Pharmaceutical stocks are traded under the ticker 4596.TSE.
Is Kubota Pharmaceutical stock price growing?▼
4596.TSE stock has fallen by -7.07% compared to the previous week, the month change is a -20.69% fall, over the last year Kubota Pharmaceutical has showed a +104.44% increase.
What is Kubota Pharmaceutical market cap?▼
Today Kubota Pharmaceutical has the market capitalization of 3.89B
When is the next Kubota Pharmaceutical earnings date?▼
Kubota Pharmaceutical is going to release the next earnings report on May 08, 2026.
What were Kubota Pharmaceutical earnings last quarter?▼
4596.TSE earnings for the last quarter are -3.49 JPY per share, whereas the estimation was N/A JPY resulting in a N/A surprise. The estimated earnings for the next quarter are N/A JPY per share.
What is Kubota Pharmaceutical revenue for the last year?▼
Kubota Pharmaceutical revenue for the last year amounts to 0 JPY.
What is Kubota Pharmaceutical net income for the last year?▼
4596.TSE net income for the last year is -6.09B JPY.
How many employees does Kubota Pharmaceutical have?▼
As of April 14, 2026, the company has 8 employees.
In which sector is Kubota Pharmaceutical located?▼
Kubota Pharmaceutical operates in the Health & Wellness sector.
When did Kubota Pharmaceutical complete a stock split?▼
Kubota Pharmaceutical has not had any recent stock splits.
Where is Kubota Pharmaceutical headquartered?▼
Kubota Pharmaceutical is headquartered in Tokyo, Japan.